In yesterday’s Wall Street session, Enfusion Inc. (NYSE:ENFN) shares traded at $11.35, up 12.27% from the previous session.
As of this writing, 6 analysts cover Enfusion Inc. (NYSE:ENFN). The consensus rating among analysts is ‘Overweight’. ENFN stock price is now 3.77% away from the 50-day moving average and -0.48% away from the 200-day moving average. The market capitalization of the company currently stands at $1.31B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
There are 2 analysts who have given it a hold rating, whereas 3 have given it a buy rating.
With the price target reduced from $15 to $10, BofA Securities Downgraded its rating from Neutral to Underperform for Enfusion Inc. (NYSE: ENFN). On January 03, 2023, Morgan Stanley Upgraded its previous ‘Equal-Weight’ rating to ‘Overweight’ on the stock reducing its target price from $13 to quote $12, while ‘BofA Securities’ rates the stock as ‘Neutral’.
In other news, Groman Dan, Chief Technology Officer sold 3,877 shares of the company’s stock on Feb 17. The stock was sold for $42,376 at an average price of $10.93. Upon completion of the transaction, the Chief Technology Officer now directly owns 89,856 shares in the company, valued at $1.02 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 17, Chief Technology Officer Groman Dan sold 3,877 shares of the business’s stock. A total of $42,376 was realized by selling the stock at an average price of $10.93. This leaves the insider owning 80,976 shares of the company worth $0.92 million. Insiders disposed of 1,523,115 shares of company stock worth roughly $17.29 million over the past 1 year. A total of 1.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ENFN stock. A new stake in Enfusion Inc. shares was purchased by FRANCHISE CAPITAL LTD during the first quarter worth $2,137,000. PEAK6 INVESTMENTS LLC invested $798,000 in shares of ENFN during the first quarter. In the first quarter, CITADEL ADVISORS LLC acquired a new stake in Enfusion Inc. valued at approximately $504,000. XTX TOPCO LTD acquired a new stake in ENFN for approximately $482,000. ROYCE & ASSOCIATES LP purchased a new stake in ENFN valued at around $473,000 in the second quarter.
Tuesday morning saw Enfusion Inc. (NYSE: ENFN) opened at $11.50. During the past 12 months, Enfusion Inc. has had a low of $7.80 and a high of $16.76. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 8.00, and a quick ratio of 8.00. The fifty day moving average price for ENFN is $10.94 and a two-hundred day moving average price translates $11.41 for the stock.
The latest earnings results from Enfusion Inc. (NYSE: ENFN) was released for Sep, 2022. The net profit margin was -12.00% and return on equity was -29.60% for ENFN. The company reported revenue of $39.15 million for the quarter, compared to $29.05 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 34.79 percent. For the current quarter, analysts expect ENFN to generate $40M in revenue.
Enfusion Inc.(ENFN) Company Profile
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.
